Algernon signs Novotech up for midstage respiratory therapy test

Lungs
Algernon Pharmaceuticals' drug is a repurposed med originally made by Sanofi more than two decades ago. (Pixabay)

Algernon Pharmaceuticals has chosen contract research organization Novotech to help run its phase 2 idiopathic pulmonary fibrosis and chronic cough trial for its experimental med NP-120 (Ifenprodil).

The study is slated to start in the next quarter, and Algernon will tap Novotech’s experience across the Asia-Pacific region. In addition, the CRO has penned a letter of intent to make an equity investment in Algernon worth around CA$220,000.

NP-120 is an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist specifically targeting the NMDA-type subunit 2B. The drug may sound familiar and is better known as Cerocral, which was initially developed by French Big Pharma Sanofi all the way back in the 1990s.

It’s currently sold as a generic drug, and Algernon is hoping to repurpose it.

Novotech CEO John Moller, M.D., said: “We are delighted to be working with Algernon on their upcoming Phase 2 study and to have signed an LOI to participate in an equity funding round of Algernon. This is a unique model to support clinical trials in our region and we look forward to a close working relationship with the Algernon team.”

Suggested Articles

Digital clinical trials firm Medable is teaming up with Covance to allow the CRO to better navigate the COVID-19 disruption via virtual trials.

There’s a mixed picture on clinical trials right now.

Contract research organization Parexel has launched what it dubs #KeepingPatientsFirst, a new research platform powered by Microsoft Azure.